02401nas a2200241   4500008004100000022001400041245006600055210006600121260008700187300001200274490000700286520154300293653003101836653001501867653001201882653002101894653002401915100002901939700003401968700003502002700002902037856009302066       2015                        eng d  a0883-911500aBlends of shellac as nanofiber formulations for wound healing0 aBlends of shellac as nanofiber formulations for wound healing  a1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLANDbSAGE PUBLICATIONS LTDcSEP  a472-4890 v303 a<p>Shellac is being used in food, pharmaceutical, and agricultural industries. It is seldom used for biomedical applications due to its poor mechanical property and instability. We designed thermoresponsive shellac-based bioactive nanofiber mats that mimic extracellular matrix to extend their utility in wound healing. Various blend compositions of shellac, gelatin, and poly(N-isopropylacrylamide) enriched with a bioactive agent, nadifloxacin, were prepared and nanofiber mats were fabricated. The morphology of the nanofiber formation was influenced by the concentration of polymer, drug, and polymer blend composition. Polymer-drug interactions and thermal and crystalline properties of nanofiber mats were analyzed. The shellac/gelatin/poly(N-isopropylacrylamide) blend of composition 3%/7%/3% (w/v) was chosen to evaluate in vitro drug release. Release studies recorded slow, constant, and sustained release for 140h. The release kinetics and mechanism confirmed zero-order release with resultant r(2) values greater than 0.99, and the Korsmeyer-Peppas release exponent (n) was slightly higher than 0.8, which indicated that drug diffusion was anomalous or non-Fickian type and drug release followed diffusion involving chain stretching. Indirect cytotoxicity studies recorded insignificant toxicity against normal human fibroblast cells. In vivo studies demonstrated that drug-loaded nanofiber mats were more suitable for faster tissue regeneration as compared to nanofiber mats without drug and commercial nadifloxacin cream.</p>10adrug release and mechanism10ananofibers10aShellac10athermoresponsive10atissue regeneration1 aVannuruswamy, Garikapati1 aRathna, Gundloori, Venkata Na1 aGadgil, Bhagyashri, Shashikant1 aGadad, Anand, Panchaksha  uhttps://library.ncl.res.in/content/blends-shellac-nanofiber-formulations-wound-healing-002917nas a2200313   4500008004100000022001400041245010400055210006900159260000800228300001100236490000800247520193700255653002102192653002602213653001402239653001202253653001102265653001702276653002402293100002102317700001802338700001502356700001902371700002002390700002302410700001702433700002602450856012702476       2025                        eng d  a0141-813000aEngineered silk matrix as a substitute for acellular dermal matrix in breast reconstruction surgery0 aEngineered silk matrix as a substitute for acellular dermal matr  cJUN  a1440170 v3123 a<p>
	Implant-based breast reconstruction is a common standard of care for breast cancer patients following mastectomy. To support implant weight and placement, surgeons utilize autologous tissues, acellular dermal matrices (ADMs), or synthetic meshes. While ADMs provide structural support, they present significant risks, including infection transmission and seroma. Conversely, synthetic meshes exhibit poor cellular adhesion, leading to inadequate tissue integration. To address these challenges, there is a need for a matrix that enhances tissue integration while minimizing infection risks and other complications. Silk fibroin (SF), a natural biopolymer, possesses excellent biocompatibility and mechanical properties. This study introduces a novel engineered silk matrix (ESM) as an advanced solution for soft tissue regeneration, specifically in breast reconstruction surgery. The present study establishes the safety of ESM and evaluates its potential a tissue regeneration matrix through extensive in-vitro and in-vivo analyses. In-vitro assays demonstrated superior cellular adhesion, proliferation of human mammary fibroblast cells (HMFCs), collagen deposition and angiogenesis in ESM compared to collagen matrices and ADMs. Safety assessments, conducted in accordance with ISO 10993 guidelines, confirmed noncytotoxic nature of ESM. Furthermore, subcutaneous implantation revealed no systemic toxicity or adverse tissue reactions. In-vivo studies utilizing a Yorkshire pig model of simulated breast reconstruction surgery, demonstrated superior performance of ESM over collagen matrices in tissue regeneration. The findings showed enhanced fibroblast density, increased collagen deposition, and improved vascularization. These results suggest that ESM is a safer and more effective alternative to ADMs in breast reconstruction, with the potential to revolutionize post-mastectomy care for breast cancer patients.</p>
10aBiocompatibility10aBreast reconstruction10aISO 1099310aPolymer10aSafety10aSilk protein10atissue regeneration1 aDeshpande, Rucha1 aShukla, Swati1 aKale, Amod1 aSayyad, Raeesa1 aKewale, Bhawana1 aDeshmukh, Narendra1 aNisal, Anuya1 aVenugopalan, Premnath  uhttps://library.ncl.res.in/content/engineered-silk-matrix-substitute-acellular-dermal-matrix-breast-reconstruction-surgery